Results 21 to 30 of about 164 (107)

Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases

Therapeutic Advances in Neurological Disorders
Background: With the development of highly effective disease-modifying treatments, vaccinations are becoming increasingly important in people with neurological autoimmune diseases.
Muriel Schraad, Mathias Mäurer, Anke Salmen, Tobias Ruck, Timo Uphaus, Vinzenz Fleischer, Felix Luessi, Maria Protopapa, Falk Steffen, Nicholas Hanuscheck, Katrin Pape, Tobias Brummer, Josef Shin, Thomas Korn, Luisa Klotz, Jan D. Lünemann, Marc Pawlitzki, Martin S. Weber, Antonios Bayas, Brigitte Wildemann, Hans-Peter Hartung, Florian Then Bergh, Clemens Warnke, Uwe K. Zettl, Achim Berthele, Aiden Haghikia, Ralf Linker, Hayrettin Tumani, Sven G. Meuth, Bernhard Hemmer, Heinz Wiendl, Tania Kümpfel, Ralf Gold, Stefan Bittner, Frauke Zipp   +34 more
doaj   +2 more sources

Diroximel Fumarate-Loaded Solid Lipid Nanoparticles (DRF-SLNs) as Potential Carriers for the Treatment of Multiple Sclerosis: Preformulation Study

International Journal of Molecular Sciences
Diroximel fumarate (DRF) is an orally administered prodrug used in multiple sclerosis (MS) treatment. Although it exhibits better gastrointestinal (GI) tolerability than its analogues, many patients still discontinue therapy due to frequent GI adverse events.
Debora Santonocito, Giuliana Greco, Maria Grazia Sarpietro, Aurélie Schoubben, Claudia Sciacca, Giuseppe Romeo, Katia Mangano, Carmelo Puglia   +7 more
openaire   +5 more sources

Effect of Diroximel Fumarate on gut dysbiosis and neuroinflammation

Neurotherapeutics
Sudhir Kumar Yadav, Ph.D., Naoko Ito, Shradha Suresh, Yaritza Rosario, Tamar Kalina, Sai L. Shankar, Ph.D., Kouichi Ito, Ph.D., Suhayl Dhib-Jalbut, M.D.   +7 more
doaj   +2 more sources

Prospective study validating a multidimensional treatment decision score predicting the 24-month outcome in untreated patients with clinically isolated syndrome and early relapsing–remitting multiple sclerosis, the ProVal-MS study [PDF]

Neurological Research and Practice
Introduction In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking.
Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, Verena S. Hoffmann, Achim Berthele, Mark Mühlau, Markus C. Kowarik, Markus Krumbholz, Makbule Senel, Verena Steuerwald, Markus Naumann, Julia Hartberger, Martin Kerschensteiner, Eva Oswald, Christoph Ruschil, Ulf Ziemann, Hayrettin Tumani, Ioannis Vardakas, Fady Albashiti, Frank Kramer, Iñaki Soto-Rey, Helmut Spengler, Gerhard Mayer, Hans Armin Kestler, Oliver Kohlbacher, Marlien Hagedorn, Martin Boeker, Klaus Kuhn, Stefan Buchka, Florian Kohlmayer, Jan S. Kirschke, Lars Behrens, Hanna Zimmermann, Benjamin Bender, Nico Sollmann, Joachim Havla, Bernhard Hemmer, the ProVal-MS study group   +37 more
doaj   +2 more sources

Vaccine response in people with multiple sclerosis treated with fumarates

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023
People with multiple sclerosis (pwMS) have an increased risk of infection. As disease-modifying therapies (DMTs) and other treatments may interact with the immune system, there may be concerns about vaccine efficacy and safety. Therefore, it is important
Matthew A. Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, Ivan Bozin, Seth Levin, Anne Gocke, Peter Wipfler   +6 more
doaj   +1 more source

Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate)

Multiple Sclerosis and Related Disorders, 2023
Bafiertam® (monomethyl fumarate [MMF]) and Vumerity® (diroximel fumarate [DRF]) are two FDA approved drug products for the treatment of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Franck S, Rousseau, Laurene, Wang, Tiffany N, Sprague, Thomas W, Lategan, Regina R, Berkovich   +4 more
openaire   +2 more sources

Multiple Sclerosis Patients Treated With Diroximel Fumarate in the Real-World Setting Have High Rates of Persistence and Adherence [PDF]

Neurology and Therapy, 2021
Persistence to multiple sclerosis (MS) disease-modifying therapy is fundamental for maximal treatment outcomes. Diroximel fumarate (DRF) is approved in the USA for relapsing MS. Following oral administration, DRF is metabolized to monomethyl fumarate, the active metabolite of dimethyl fumarate (DMF).
Jacob Liseno, Brittney Lager, Catherine Miller, Sai L. Shankar, Jason P. Mendoza, James B. Lewin   +5 more
openaire   +2 more sources

sj-pdf-2-msj-10.1177_13524585231205708 – Supplemental material for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2023
Supplemental material, sj-pdf-2-msj-10.1177_13524585231205708 for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Barry A Singer, Douglas L Arnold, Jelena
Mark S Freedman (5235176), Ting Wang (16292), Tjalf Ziemssen (352981), Barry A Singer (7699400), Matthew Scaramozza (17311772), Sai L Shankar (17311775), Sibyl Wray (4656925), Miguel Angel Hernandez Perez (17311766), Hailu Chen (7820795), Jelena Drulovic (423245), Krzysztof Selmaj (3486809), Annette Wundes (5444552), Seth Levin (17311769), Wanda Castro-Borrero (5339651), Mark Gudesblatt (7533740), Ralf Gold (42956), Donald Negroski (12013663), Douglas L Arnold (5321081), Christopher C LaGanke (6386588), Robert T Naismith (5510369), Elzbieta Jasinska (8255024), Jiwon Oh (8349804), Florian Then Bergh (20098)   +22 more
core   +1 more source

Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study

, 2020
BACKGROUND: Diroximel fumarate (DRF) is a novel oral fumarate approved in the USA for relapsing forms of multiple sclerosis. DRF is converted to monomethyl fumarate, the pharmacologically active metabolite of dimethyl fumarate (DMF).
et al.,, Naismith, Robert T
core   +2 more sources

sj-docx-1-msj-10.1177_13524585231205708 – Supplemental material for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

, 2023
Supplemental material, sj-docx-1-msj-10.1177_13524585231205708 for Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study by Barry A Singer, Douglas L Arnold ...
Mark S Freedman (5235176), Ting Wang (16292), Tjalf Ziemssen (352981), Barry A Singer (7699400), Matthew Scaramozza (17311772), Sai L Shankar (17311775), Sibyl Wray (4656925), Miguel Angel Hernandez Perez (17311766), Hailu Chen (7820795), Jelena Drulovic (423245), Krzysztof Selmaj (3486809), Annette Wundes (5444552), Seth Levin (17311769), Wanda Castro-Borrero (5339651), Mark Gudesblatt (7533740), Ralf Gold (42956), Donald Negroski (12013663), Douglas L Arnold (5321081), Christopher C LaGanke (6386588), Robert T Naismith (5510369), Elzbieta Jasinska (8255024), Jiwon Oh (8349804), Florian Then Bergh (20098)   +22 more
core   +1 more source